Are you a Veteran of the United States Armed Forces?

Please complete a short survey about prostate cancer care for Veterans to help us learn what's working well and what needs improvement in the care Veterans receive.

Veterans prostate cancer care survey Complete the Survey

FDA Grants Janssen Biotech’s Apalutamide Priority Review Designation to Treat Non-Metastatic CRPC

The U.S. Food and Drug Administration (FDA) has granted priority review status to apalutamide — an investigational androgen receptor inhibitor — to treat men with non-metastatic castration-resistant prostate cancer (CRPC).

Read more.

Source: Prostate Cancer News Today

Share